Preparation of honokiol-loaded chitosan microparticles via spray-drying method intended for pulmonary delivery

Drug Delivery

Volumn 16, Issue 3, 2009, Pages 160-166

  Li, Xingyi ^a   Guo, Qingfa ^a   Zheng, Xiuling ^a   Kong, Xiangye ^a   Shi, Shuai ^a   Chen, Lijuan ^a   Zhao, Xia ^a   Wei, Yuquan ^a   Qian, Zhiyong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Chitosan; Honokiol nanoparticles; In vitro release; Spray drying

Indexed keywords

CHITOSAN; HONOKIOL; MANNITOL; NANOPARTICLE; BIPHENYL DERIVATIVE; DRUG CARRIER; EXCIPIENT; LIGNAN;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG TRANSPORT; DRY POWDER; IN VITRO STUDY; INFRARED SPECTROSCOPY; LUNG ALVEOLUS EPITHELIUM; NANOPHARMACEUTICS; PARTICLE SIZE; PRIORITY JOURNAL; SPRAY DRYING; SURFACE PROPERTY; CHEMISTRY; DRUG STABILITY; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; LUNG; METABOLISM; PHARMACEUTICS; POWDER; RESPIRATORY TRACT MUCOSA;

ADMINISTRATION, INHALATION; ADMINISTRATION, INTRANASAL; BIPHENYL COMPOUNDS; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EXCIPIENTS; LIGNANS; LUNG; MANNITOL; NANOPARTICLES; POWDERS; RESPIRATORY MUCOSA; TECHNOLOGY, PHARMACEUTICAL;

EID: 70349312538     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.1080/10717540902738341     Document Type: Article

References (25)

1. Smith PL. (1997). Peptide delivery via the pulmonary route: a valid approach for local and systemic delivery. J Contr Rel, 46, 99-106.
2. Bosquillon C, Préat V, Vanbever R. (2004). Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats. J Contr Rel, 96, 233-244
3. Shoyele SA, Cawthorne S. (2006). Particle engineering techniques for inhaled biopharmaceuticals. Adv Drug Deliv Rev, 58, 1009-1029
4. Byron PR. (1990). Determinants of drug and polypeptide bioavailability from aerosols delivered to the lung. Adv Drug Deliv Rev, 5, 107-132
5. Grenha A, Seijo B, Remuñán-López C. (2005). Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci, 25, 427-437
6. Broadhead J, Edmond-Rouan SK, Rhodes CT. (1992). The spray drying of pharmaceuticals. Drug Dev Ind Pharm, 18, 1169-1206
7. Bosquillon C, Lombry C, Préat V, Vanbever R. (2001). Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J Contr Rel, 70, 329-339
8. Johnson KA. (1997). Preparation of peptide and protein powders for inhalation. Adv Drug Deliv Rev, 26, 3-15.
9. Irngartinger M, Camuglia V, Damm M, Goedea J, Frijlink HW. (2004). Pulmonary delivery of therapeutic peptides via dry powder inhalation: effects of micronisation and manufacturing. Eur J Pharm Biopharm, 58, 7-14.
10. Niven RW, Lott FD, Ip AY, Cribbs JM. (1994). Pulmonary delivery of powders and solutions containing recombinant human granulocyte colony-stimulating factor. Pharm Res, 11, 1101-1109
11. Skyler, SJ, Cefalu WT, Kourides IA, Landschulz WH, Balagtas CC, Cheng SL, Gelfand RA. (2001). Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomized proof-concept study. Lancet, 357, 331-335
12. Ventura CA, Tommasini S, Crupi E, Giannone I, Cardilec V, Musumecib T, Puglisi G. (2008). Chitosan microspheres for intrapulmonary administration of moxifloxacin-Interaction with biomembrane models and in vitro permeation studies. Eur J Pharm Biopharm, 68, 235-244
13. Alpar HO, Somavarapu S, Atuah KN, Bramwell VW. (2005). Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev, 57, 411-430
14. Yamamoto H, Kuno Y, Sugimoto S, Takeuchi H, Kawashima Y. (2005). Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J Contr Rel, 102, 373-381
15. Vasir JK, Tambwekar K, Garg S. (2003). Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm, 255, 13-32.
16. Griese M, Reinhardt D. (1998). Smaller sized particles are preferentially taken up by alveolar type II pneumocytes. J Drug Target, 5, 471-479
17. Dickinson PA, Howells SW, Kellaway IW. (2001). Novel nanoparticles for pulmonary drug administration. J Drug Target, 9, 295-302.
18. Clark A. (2002). Formulation of proteins and peptides for inhalation. Drug Deliv Syst Sci, 2, 73-77
19. Makino K, Yamamoto N, Higuchi K, Harada N, Ohshima H, Terada H. (2003). Phagocytic uptake of polystyrene microspheres by alveolar macrophages: effects of the size and surface properties of the microspheres. Colloids Surf B Biointerf, 27, 33-39
20. Chen L, Zhang Q, Yang G, Fan L, Tang J, Garrard I, Ignatova S, Fisher D, Sutherland IA. (2007). Rapid purification and scale-up of honokiol and magnolol using high-capacity high-speed counter- current chromatography. J Chromatography A, 1142, 115-122
21. Gou ML, Li XY, Dai M, Wang XH, Gong CY, Deng HX, Xie Y, Wang K, Zhao X, Qian ZY, Wei YQ. (2008). A novel injectable local hydrophobic drug delivery system: biodegradable nanoparticles in thermo-sensitive hydrogel. Int J Pharm, 359, 228-233
22. Rattes ALR, Oliveira WP. (2007). Spray drying conditions and encapsulating composition effects on formation and properties of sodium diclofenac microparticles. Powder Technol, 171, 7-14.
23. De Villiers MM. (2005). Powder flow and compressibility. In: Ghosh TK, Jasti BR,eds. Theory and Practice of Contemporary Pharmaceutics. Boca Raton, FL: CRC Press, 298-299
24. Learoyd TP, Burrows JL, French E, Seville PC. (2008). Chitosanbased spray-dried respirable powders for sustained delivery of terbutaline sulfate. Eur J Pharm Biopharm, 68, 224-234
25. Chan HK. (2006). Dry powder aerosol drug delivery-opportunities for colloid and surface scientists. Colloids Surf A Physicochem Eng Aspects, 284-5, 50-55